Other News To Note
Wednesday, December 14, 2011
EnVivo Pharmaceuticals Inc., of Watertown, Mass., said the journal Neuropharmacology published data confirming the mechanism of action of its lead program EVP-6124 and demonstrating that the compound is a potent and highly selective agonist of alpha-7 neuronal nicotinic acetylcholine receptors in the brain.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.